LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Kodu・Aktsiate loetelu・Cassava Sciences Inc

Cassava Sciences Inc

Avatud

SektorTervishoid

2.05 -4.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.04

Max

2.15

Põhinäitajad
By Trading Economics
Sissetulek	33M -11M
Müük	840K 840K
Kasumimarginaal	-1,286.548
Töötajad	30
EBITDA	35M -11M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	2. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-4.3M 142M
Eelmine avamishind	6.7
Eelmine sulgemishind	2.05

Uudiste sentiment

By Acuity

27%

73%

56 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

1.56 / 1.7 Toetus ja vastupanu

Cassava Sciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

Võrdlus sarnastega

Hinnamuutus

Cassava Sciences Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Cassava Sciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.56 / 1.7Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

56 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.